Professionals | Aplastic Anemia & MDS International Foundation

Professional Webinars

Hero Image

Recorded Programs


Virtual Tumor Board: Diagnosis Management of Myelodysplastic Syndromes

Dates Available: May 26, 2020 to May 25, 2021

Faculty:

  • David P. Steensma, MD, FACP​​​​​​
  • Reza Nejati, MD
  • Ilene Galinsky, BSN, MSN, ANP-C

Watch Program Here
 



The Clinical Management of Myeloid Malignancy: The Coming Age of Targeted Therapies

Friday, December 6, 2019 | 12:00-4:00 pm
Orange County Convention Center
Orlando, FL

This Satellite Symposium, which preceded the 61st ASH Annual meeting, was organized by the Cleveland Clinic Taussig Cancer Institute Leukemia Program and the Aplastic Anemia and MDS International Foundation.

The complimentary enduring program provides an in-depth and up-to-date review of research related to the biology, prognosis, natural history, and therapeutic management of patients with aplastic anemia, paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). The program brought together leaders in disease research and clinical practice to explore solutions on improving the care of patients.

Watch program here

 


Riding the Wave: Clinical Management of Myeloid Malignancy in an Era of Novel Therapies

Friday, November 30, 2018 | 7:00-11:00 am
Manchester Grand Hyatt
San Diego, CA

This Satellite Symposium was organized by the Cleveland Clinic Taussig Cancer Institute Leukemia Program and the Aplastic Anemia and MDS International Foundation, preceding the 60th ASH Annual Meeting.

This CME certified activity provides an in-depth and up-to-date review of research related to the biology, prognosis, natural history, and therapeutic management of patients with MDS, PHN, AML and myeloid malignancies. This program brings together leaders in disease research and clinical practice to explore solutions to improving the care of these patient populations.

Watch program here



Myelodysplastic Syndromes Transitioning to Acute Myeloid Leukemia

Thursday, January 23, 2020 | 1:00 pm ET

At the conclusion of this program, participants will be able to:

  • Describe a management strategy for high-risk MDS/AML based on the clinical presentation, diagnostic workup and recent research findings
  • ​Explain the role of genetic testing in risk assessment and stratification for this patient population
  • Identify emerging treatment options for high-risk MDS and secondary AML
  • Discuss the roles of a multidisciplinary health care team in addressing treatment goals and providing patient education to improve outcomes, including guiding patients and caregivers in decision making, financial issues, and palliative care options
  • Identify resources for support and education for patients

Watch program here

 


ONS Congress Satellite Symposium

The Many Facese of Myelodysplastic Syndromes – Managing Evolving Therapies and Counseling Patients

This dinner symposium recorded at the 2019 ONS Annual Congress in Anaheim, CA focused on recent advances in diagnosing and treating myelodysplastic syndromes and related diseases, including AML and MDS/MPN overlap, and the role of nurses in disease management and care coordination. Topics include the latest developments in precision medicine for diagnosing and treating myeloid malignancies; emerging treatment options for low-risk MDS, high-risk MDS, AML, and MDS/MPN overlap; disease management; psychosocial considerations and palliative care to improve the quality-of-life for this patient population. Case studies are used to illustrate treatment decision-making and therapeutic challenges.

Watch program here
 


BMT and Immunotherapies for Pediatric Leukemia: Current and Novel Treatments and Financial Implications

Sponsored jointly by the National Marrow Donor Program® / Be The Match® and the Aplastic Anemia and MDS International Foundation.

In this recorded webinar, you'll learn that bone marrow transplant (BMT) and immunotherapies continue to quickly evolve for pediatric leukemia, varying in the pathophysiology and management. For health professionals, knowledge of these treatment options and potential toxicities is necessary to manage and provide patients with safe and effective evidence-based care. When choosing these treatment options, families can face additional financial decisions and need assistance to manage the financial implications.

Speakers:

  • Vicki Szenes, MS, RN, CPNP, CPHON®, Pediatric Nurse Practitioner ,
    Memorial Sloan-Kettering Cancer Center 
  • Meghan Wellenbrink, BSN, RN, CPHON, CAR-T Cell Clinical Nurse Coordinator, 
    Memorial Sloan-Kettering Cancer Center

Watch program here
 


Myelodysplastic Syndromes in Older Adults: Treatment Options and Support Strategies

Sponsored jointly by the National Marrow Donor Program® / Be The Match® and the Aplastic Anemia and MDS International Foundation.

Allogeneic hematopoietic cell transplantation (HCT) is the only therapy for MDS with curative potential. Of the estimated 15,000 to 20,000 US patients diagnosed annually, >80% are >age 70 years. Care of patients with MDS requires understanding the disease in the context of an older population, and tailoring approaches to both disease risk and patient suitability for therapy.

In this recorded continuing education webinar a physician and nurse practitioner will present current research and case examples to illustrate treatment options and common experiences for older patients with MDS and their families. The goal of this activity is to ensure that members of a multidisciplinary team have the knowledge and skills necessary to apply the standards of care to their practice and healthcare setting for patients with MDS. It is accredited for hematology/oncology nurses; hematology, oncology social workers at intermediate to advanced levels of practice, experience and licensure; and clinical laboratory professionals.

Watch program here

Speakers:

  • Marlise R. Luskin, MD, MSCE, Physician in Dana-Farber’s Adult Leukemia program
  • Ilene Galinsky, NP, Senior Program Research Nurse Practitioner for the Adult Leukemia Program with the Dana Farber Cancer Institute (DFCI) and Brigham and Women’s Hospital /BWH in Boston, Massachusetts